Ardelyx Earnings Call Highlights Rapid Growth, Rising Costs

Ardelyx Inc ((ARDX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Ardelyx’s latest earnings call balanced robust commercial momentum with candid acknowledgment of mounting costs and competitive uncertainty. Management highlighted strong double‑digit revenue growth, accelerating Ibsrela uptake, and solid pipeline execution, while noting that higher operating expenses, seasonality, and gross‑to‑net pressure are keeping profitability just out of reach for now.

Strong Q1 Revenue Growth

Total product revenues reached $93.4 million in the first quarter of 2026, rising 38% year over year from $67.8 million. Management attributed the bulk of this expansion to continued demand growth for Ibsrela, underscoring the drug’s role as the primary engine of Ardelyx’s current top‑line performance.

Ibsrela Momentum and Guidance

Ibsrela delivered $70.1 million in Q1 revenue, up 58% from the prior year, reinforcing its status as the company’s flagship asset. Ardelyx reaffirmed 2026 Ibsrela guidance of $410 million to $430 million and a long‑term target of at least $1 billion in annual Ibsrela revenue by 2029, implying roughly 38% compound annual growth.

Exposa Growth and Targets Reaffirmed

Exposa reported $23.3 million in Q1 revenue, which appeared roughly flat year over year due to a favorable $3.8 million return reserve recorded in Q1 2025. Adjusting for that one‑time effect, paid prescriptions grew about 19%, and management reiterated a long‑term Exposa revenue target of $750 million and 2026 guidance of $110 million to $120 million.

Pipeline Progress: EXCEL Phase 3 and Pediatrics

The company launched the EXCEL Phase 3 trial of Ibsrela in chronic idiopathic constipation, activating all pre‑identified trial sites in under four months and guiding to complete enrollment by year‑end with topline data expected in 2027. Ardelyx is also advancing pediatric studies that could support label expansion, potential six‑month exclusivity extension, and is backed by an Orange Book‑listed commercial formulation patent running to 2099.

Next-Generation NHE3 Program

Ardelyx’s next‑generation NHE3 inhibitor program, referred to as 531, is progressing through IND‑enabling studies. Management framed this effort as a way to extend the company’s reach into additional therapeutic areas over time, potentially broadening the clinical and commercial footprint beyond the current Ibsrela and Exposa franchises.

Commercial Execution and Access Initiatives

Commercial initiatives such as the Ibsrela Pharmacy Network and additional field reimbursement managers are helping drive better pull‑through. The specialty pharmacy channel now accounts for roughly 30% of volume, and management reported higher fill rates and on average one extra refill per year for patients using the network.

Improved Losses and Strengthened Balance Sheet

Net loss narrowed to $37.6 million, or $0.15 per share, compared with $41.1 million, or $0.17 per share, a year earlier. The company ended the quarter with $238.1 million in cash, cash equivalents, and short‑term investments, and refinanced its loan with SLR to extend maturity, reduce its cost of capital, and preserve a $100 million undrawn borrowing capacity.

Rising Operating Expenses and Planned OpEx Ramp

Operating expenses continue to climb as Ardelyx invests behind growth, with SG&A rising to $102.3 million from $83.2 million and R&D increasing to $20.2 million from $14.9 million. Management guided to roughly $520 million in total operating expenses for 2026, representing around 25% growth and signaling sustained pressure on near‑term profitability.

Exposa GAAP Complexity and Market Challenges

While underlying Exposa prescriptions are growing, the GAAP revenue line remains noisy due to prior‑year return reserve adjustments and reimbursement dynamics. Management acknowledged that payer behavior and ongoing dialysis market challenges can obscure the franchise’s true trajectory and may continue to inject volatility into reported results.

Seasonality, Weather and Gross-to-Net Pressure

First‑quarter results were also influenced by typical Q1 seasonality and two severe winter storms, which temporarily disrupted distribution and demand in certain regions. Blended gross‑to‑net ran at about 36.4% in the quarter, above the low‑30s level management expects for the full year, reflecting heightened early‑year copay and deductible dynamics.

Ongoing Losses, Cash-Flow Risk and Competition

Despite progress, the company remains loss‑making and has yet to demonstrate durable cash‑flow positivity, with operating expenses tracking near the low end of revenue guidance. Management also flagged competitive uncertainty from GLP‑1 programs in development for IBS‑C, including those from Lilly, which could pose long‑term risk to Ibsrela if future data show strong efficacy in overlapping patient groups.

Guidance and Outlook

Ardelyx reaffirmed 2026 product revenue guidance of $520 million to $550 million, implying 38% to 46% growth, with Ibsrela expected to deliver $410 million to $430 million and Exposa $110 million to $120 million. Management anticipates quarter‑over‑quarter demand increases, aims for at least $1 billion in Ibsrela revenue by 2029, and plans to support this growth through continued commercial investment, pipeline execution, and disciplined balance‑sheet management.

Ardelyx’s earnings call painted the picture of a growth story still in investment mode, with Ibsrela anchoring a rapidly expanding revenue base and Exposa quietly building momentum beneath GAAP noise. Investors will be watching whether strong demand, pipeline catalysts, and disciplined financing can outpace rising expenses and emerging competition on the path to sustainable profitability.